Result:Weak
| Metric | Value (₹ Cr) | vs Q4 FY26 |
|---|---|---|
| Revenue | 3.13 | 28.7% |
| Total Income | 3.18 | 29.7% |
| Expenditure | 2.99 | 33.2% |
| PBT | 0.19 | 250.3% |
| Net Profit | 0.14 | 152.4% |
| OPM | 5.80% | 5.18pp |
| NPM | 4.50% | 3.25pp |
| EPS | 0.01 | 0.0% |
No YoY comparison is available, but OPM of 5.8% and NPM of 4.5% are thin for a pharma company, signaling below-par core profitability on a very small revenue base.
Informational and educational content only. Not investment advice.